Abstract One of the main bottlenecks of anticancer drug development is the assessment of the in vivo relevance of emerging therapies. Previously, drugs that suppress the in vivo progression of neuroblastoma have been hard to identify. To address this problem, we propose a new computational technique, onTARGET, that enables researchers to select, with good accuracy, compounds that are likely to induce changes in cellular pathways that are consistent with specific clinical outcomes and subgroups. onTARGET prediction is based on an integration of massive expression and other data resources, including the NIH LINCS dataset (with 1,300,000 expression profiles), the NIH TARGET and R2-AMC neuroblastoma cohorts, and our own in-house databases. In a first step, the datasets are preprocessed by factor analysis to remove systematic bias in these large data sets. In a second step, Bayesian statistics are applied to prioritize compounds whose cellular responses match clinically relevant differences between patient subsets, such as MYCN status, survival hazard ratio, or histopathological assessment. To evaluate the method, we used onTARGET prediction to identify compounds and gene targets relevant for clinical outcomes in the NIH-TARGET (n=249) and R2-AMC (n=98) neuroblastoma cohorts. The algorithm confirmed existing targets and made interesting predictions. Of 50 the top-ranking compounds associated with a survival outcome, agents targeting the mTOR/PI3K axis are highly prevalent. The algorithm correctly predicts targeting of the MYC pathway, and predicts possible modulators of MYC signaling, such as TRRAP, AURKA and BMP2. In addition to nominating agents with a favorable outcome, the algorithm can also flag compounds that might worsen prognosis, further facilitating the prioritization of targets for evaluation. In summary, onTARGET may guide target selection for neuroblastoma studies and can be adapted for other cancers as well. The many targets that were identified immediately suggest an opportunity for continued evaluation in cells and in vivo models. This work has been initiated in collaboration with researchers at Lund University. Citation Format: Elin Almstedt, Ingrid Lönnstedt, Cecilia Krona, Sven Nelander. onTARGET: a new computational strategy to predict in vivo relevant targets against neuroblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 686. doi:10.1158/1538-7445.AM2017-686
Read full abstract